Recap: Redhill Biopharma Q1 Earnings

Shares of Redhill Biopharma RDHL rose 4.6% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 66.67% year over year to ($0.05), which beat the estimate of ($0.24).

Revenue of $1,056,000 decreased by 39.21% from the same period last year, which missed the estimate of $4,380,000.

Looking Ahead

Redhill Biopharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 27, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/cgzdt8vg

Technicals

Company's 52-week high was at $9.12

52-week low: $3.26

Price action over last quarter: Up 51.80%

Company Profile

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!